NEOGHealthcare · Medical DevicesThe 4 Wall Street analysts covering Neogen Corp. hold a median 12-month price target of $14 — +12.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Neogen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Quality (57): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (31): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NEOG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.4% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Guggenheim | Maintains | Buy | $12 → $14 |
| 26 Aug 2026 | Piper Sandler | Upgrade | Overweight | $13 → $14 |
| 26 Aug 2026 | Piper Sandler | Upgrade | Overweight | — |
| 3 Aug 2026 | Piper Sandler | Reiterates | Neutral | $11 → $13 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Neutral | — |
| 12 Jan 2026 | Piper Sandler | Reiterates | Neutral | — |
| 12 Jan 2026 | Piper Sandler | Reiterates | Neutral | $6.50 → $10 |
| 9 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Jan 2026 | Guggenheim | Maintains | Buy | $8.00 → $12 |
| 10 Dec 2025 | CJS Securities | Upgrade | Market Outperform | — |
| 16 Oct 2025 | Piper Sandler | Reiterates | Neutral | — |
| 29 Sept 2025 | CJS Securities | Initiates | Market Perform | — |
| 29 July 2025 | William Blair | Downgrade | Market Perform | — |
| 30 June 2025 | Guggenheim | Maintains | Buy | — |
| 22 Apr 2025 | Piper Sandler | Maintains | Neutral | — |
| 14 Apr 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Apr 2025 | Guggenheim | Maintains | Buy | — |
| 21 Jan 2025 | Piper Sandler | Reiterates | Neutral | — |
| 19 Dec 2024 | Guggenheim | Initiates | Buy | — |
| 6 Aug 2024 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NEOG appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Neogen Corp. returned +106.1% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 39% of US stocks
Cheaper than 62% of US stocks
Cheaper than 8% of US stocks
Higher than 44% of US stocks
Higher than 37% of US stocks
Higher than 59% of US stocks
Higher than 31% of US stocks
Higher than 22% of US stocks
Higher than 41% of US stocks
Higher than 43% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Neogen Corp. has a market value of $2.6B and an enterprise value of $3.2B.
Revenue in the twelve months to 31 May 2026: $870.4M. The latest quarter grew 6.5% year on year.
Net income over the same four quarters: −$7.9M, a −0.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.04.
Free cash flow in the twelve months to 31 May 2026: $31.9M.
Trailing P/E: 865.0×; forward P/E: 26.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Neogen Corp. employs 2,636 people — $330K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neogen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Neogen Corporation announced it will participate in the 2026 UBS Global Healthcare Conference in Palm Beach Gardens, Florida, on Tuesday, November 10.
Why it matters — NEOG watchers may note the company’s scheduled participation in an upcoming healthcare industry conference.
Zacks compares Neogen with Where Food Comes From, saying Neogen leads in revenue growth and recovery potential. It notes that higher debt and integration risks complicate the comparison.
Why it matters — NEOG watchers may want to weigh the cited growth and recovery advantages against the company’s debt and integration risks.
The headline reports that the Law Offices of Howard G. Smith is contacting Neogen shareholders who lost money regarding a securities fraud investigation. The excerpt provides no further details.
Why it matters — NEOG shareholders may take note of the reported investigation and outreach concerning investors who incurred losses.
The Law Offices of Frank R. Cruz said it is continuing an investigation into Neogen on behalf of investors concerning possible violations of federal securities laws.
Why it matters — The investigation is relevant to NEOG watchers because it concerns potential securities-law issues involving the company and its investors.
Zacks highlighted ICUI, NEOG and TRLV as medical product stocks positioned to benefit from industry tailwinds, and said they could be worth adding to investors’ portfolios.
Why it matters — The article presents NEOG as one of three companies it considers well positioned to benefit from industry tailwinds.
The 4 Wall Street analysts covering Neogen Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Neogen Corp., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neogen Corp. 96 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Neogen Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +12.4% from the last close, and Ticker Nerd's factor model ranks Neogen Corp. 96 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neogen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEOG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.
Neogen Corp. returned +106.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries.
The most recent item we track (Business Wire, 3 Nov 2026): "Neogen® To Participate in 2026 UBS Global Healthcare Conference". Neogen Corporation announced it will participate in the 2026 UBS Global Healthcare Conference in Palm Beach Gardens, Florida, on Tuesday, November 10.
Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries. Its Food Safety segment provides test kits, culture media, and related products used by food and feed producers, processors, laboratories, and regulators to detect pathogens, allergens, toxins, drug residues, and sanitation issues. Its Animal Safety segment supplies veterinary instruments, consumables, disinfectants, rodent and insect control products, pharmaceuticals, vaccines, and diagnostic products for veterinarians, livestock producers, and animal health distributors. Neogen Corp. also offers genomics-related services and other products that support animal health and food production workflows. Headquartered in Lansing, Michigan, the company serves customers across food processing, animal protein, agriculture, and companion-animal markets in the United States and internationally.
CEO Mr. Mikhael Nassif · 2,636 employees · United States · https://www.neogen.com
